BOSTON, Sept. 22 Xoft, Inc., developer of the Axxent(R)Electronic Brachytherapy (eBx) System, which delivers non-radioactive,electronic therapy directly to cancer sites with minimal radiation exposure tosurrounding healthy tissue, will showcase early clinical experience with itsgrowing suite of oncology treatment technologies here at the 49th AmericanSociety for Therapeutic Radiology and Oncology (ASTRO) Meeting, September21-24. Developed for the treatment of early stage breast cancer, the AxxentSystem also has applicators for endometrial and rectal indications and is FDAcleared for use in the treatment of other cancers or conditions whereradiation therapy is indicated. To date, more than 35 Axxent Systems havebeen shipped nationwide.
Initial data from the phase IV study, "Early experience with an electronicbrachytherapy technique for intracavitary accelerated partial breastirradiation (APBI)," will be presented at an Industry Satellite Symposiumhosted by Xoft in conjunction with the ASTRO. The presentation will be madeby Vivek Mehta, MD, director, Center for Advanced Targeted Radiotherapies atSwedish Cancer Center in Seattle and Radiation Oncology Principal Investigatorfor the study.
According to Dr. Mehta, clinical experience with the Axxent System formany study patients followed to six months and beyond demonstrates that theX-Ray-based, non-isotopic treatment is a viable option for adjuvant therapyfor early-stage breast cancer. After the tumor had been removed withlumpectomy surgery, the Axxent System was used to deliver radiation therapydirectly to the tumor bed over five days instead of the standard five to sevenweek course of treatment. "While we will be monitoring these patients for thenext five years, this data is very exciting as it confirms what we asinvestigators hoped it would from the start -- that Electronic Brachytherapyis a safe and clinically promising alternative for accelerated partial breastirradiation."
The Symposium program, titled "Electronic Brachytherapy: Innovation andConversations" will also feature a panel of leading radiation oncologists andbreast surgeons discussing new indications for Electronic Brachytherapy,including the treatment of endometrial cancer and intraoperative radiationtherapy. Program highlights include:
-- Not Just for APBI Anymore -- the Latest Indications for ElectronicBrachytherapy: With the clearance from FDA for the practice of radiationoncology, the Axxent System has now established itself as an oncology platformtechnology. Adam Dickler, MD, Department of Radiation Oncology, Little Companyof Mary Hospital, Evergreen Park, IL, will review early experience with XoftAxxent Vaginal cylinders in the treatment of endometrial cancer and LittleCompany's early experience utilizing the Axxent System to deliverIntraoperative Radiation Therapy (IORT) for early-stage breast cancerpatients. With IORT, eligible patients can have their tumors removed andpotentially receive their entire regimen of radiation therapy in a single day.
-- What's Next? Electronic Brachytherapy and the Future of RadiationOncology: Without the need for a heavily-shielded vault, the accessibility ofthe Axxent Electronic Brachytherapy System can significantly expand the reachof radiation oncology. Mark Carol, MD, Xoft Chief Medical Officer and renownedthought leader in advances in oncology, will discuss the potential for currentand next generation treatments using the Axxent X-ray Source.
-- Lightning Round: Two luminaries in the area of APBI will challenge eachother and the audience with thought provoking ideas and opinions on theselatest breakthroughs in breast cancer treatment. Presented by Peter Beitsch,MD, director, Dallas Breast Center, Dallas, TX and David Wazer, MD, professorand chairman, Department of Radiation Oncology, Tufts University School ofMedicine, Boston, MA and the Department of Radiati